CRSP CRISPR Therapeutics
- 57.960
- -0.760-1.29%
- 58.000
- +0.040+0.07%
CRISPR Therapeutics News
Needham: Reiterated CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, target price of $90.00.
CRISPR Therapeutics Analyst Ratings
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target
CRISPR Therapeutics Analyst Ratings
Mizuho Maintains Buy on CRISPR Therapeutics, Raises Price Target to $99
Crispr Therapeutics AG (CRSP) Receives a Buy From Truist Financial
Damo: The CRISPR Therapeutics (CRSP.US) holdings reduction rating was maintained, and the target price was adjusted from $46.00 to $48.00.
CRISPR Therapeutics Analyst Ratings
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating
CRISPR Therapeutics Analyst Ratings
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept
Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $112
CRISPR Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Truist Cuts CRISPR Therapeutics Target to $120 From $160
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Crispr Therapeutics AG (CRSP) and Gilead Sciences (GILD)
Crispr Therapeutics AG: Maintained Buy Rating With Adjusted Price Target Following FDA Approval and Strategic Pipeline Prioritization
Crispr Therapeutics AG (CRSP) Receives a Buy From Oppenheimer
Hold Rating on Crispr Therapeutics AG Amid Promising Programs and Market Strategy Considerations
Analysts' Top Healthcare Picks: AbbVie (ABBV), Crispr Therapeutics AG (CRSP)
Analysis
Price Target
No Data
